Comparative Effectiveness of Statins Vs PCSK9 Inhibitors in High-Risk CV patients

Atiq Ur Rehman; Faiz Ullah; Rahim Dil Khan; Ajmal Khan

doi:10.70749/ijbr.v3i4.1238

Authors

Atiq Ur Rehman Peshawar Institute of Cardiology, Peshawar, Pakistan
Faiz Ullah Department of Cardiology, Hayatabad Medical Complex, Peshawar, Pakistan
Rahim Dil Khan Department of Cardiology, Hayatabad Medical Complex, Peshawar, Pakistan
Ajmal Khan Rehman College of Allied Health Science, Rehman Medical Institute, Peshawar, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v3i4.1238

Keywords:

PCSK9 Inhibitors, Statins, LDL-C, Cardiovascular Risk, Lipid-Lowering Therapy

Abstract

Introduction: Cardiovascular disease continues to be a significant health issue, which is responsible for the highest mortality rates worldwide; dyslipidemia is an easily changeable risk factor. Statins are the first-line drugs used for the management of lipid disorders, but currently, numerous high-risk patients do not achieve LDL-C targets, which makes it necessary to use PCSK9 inhibitors. Objective: To compare the effectiveness and safety of statins versus PCSK9 inhibitors in reducing LDL-C levels and cardiovascular events in high-risk cardiovascular patients. Materials and Method: This cross-sectional study was done at Hayatabad Medical Complex Peshawar, Pakistan from March, 2024 to August, 2024. 180 high-risk patients were selected for the analysis and randomized into statin and PCSK9 inhibitor groups. Data regarding LDL-C levels, cardiovascular events, and adverse effects were examined. Results: PCSK9 inhibitors showed significantly greater LDL-C reduction (58.2% vs. 36.6%, p<0.001) and fewer cardiovascular events (6.6% vs. 15.5%, p=0.03) compared to statins. Conclusion: The study established that PCSK9 inhibitors are more potent and safer than statins for high cardiovascular risk patients.

Downloads

Download data is not yet available.

References

Sanz-Cuesta, B.E. and Saver, J.L., 2021. Lipid-lowering therapy and hemorrhagic stroke risk: comparative meta-analysis of statins and PCSK9 inhibitors. Stroke, 52(10), pp.3142-3150.

https://doi.org/10.1161/strokeaha.121.034576

Mercep, I., Strikic, D., Hrabac, P., Pecin, I. and Reiner, Ž., 2024. PCSK9 inhibition: From effectiveness to cost-effectiveness. Frontiers in Cardiovascular Medicine, 11, p.1339487.

https://doi.org/10.3389/fcvm.2024.1339487

Khan, S.U., Yedlapati, S.H., Lone, A.N., Hao, Q., Guyatt, G., Delvaux, N., Bekkering, G.E.T., Vandvik, P.O., Riaz, I.B., Li, S. and Aertgeerts, B., 2022. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. bmj, 377.

https://doi.org/10.1136/bmj-2021-069116

Jiang, Y., Wang, Y., Ma, S., Qian, L., Jing, Y., Chen, X. and Yang, J., 2025. Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis. Frontiers in Cardiovascular Medicine, 11, p.1415668.

https://doi.org/10.3389/fcvm.2024.1415668

Burnett, H., Fahrbach, K., Cichewicz, A., Jindal, R., Tarpey, J., Durand, A., Di Domenico, M., Reichelt, A. and Viljoen, A., 2022. Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Current Medical Research and Opinion, 38(5), pp.777-784.

https://doi.org/10.1080/03007995.2022.2049164

Imbalzano, E., Ilardi, F., Orlando, L., Pintaudi, B., Savarese, G. and Rosano, G., 2023. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal-Cardiovascular Pharmacotherapy, 9(4), pp.318-327.

https://doi.org/10.1093/ehjcvp/pvad019

Xiang, Y., Gan, L., Du, H., Hao, Q., Aertgeerts, B., Li, S. and Hu, M., 2023. Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults. International Journal of Technology Assessment in Health Care, 39(1), p.e53.

https://doi.org/10.1017/s0266462323000296

Toth, P.P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E.S. and Worth, G.M., 2022. Network meta‐analysis of randomized trials evaluating the comparative efficacy of lipid‐lowering therapies added to maximally tolerated statins for the reduction of low‐density lipoprotein cholesterol. Journal of the American Heart Association, 11(18), p.e025551.

https://doi.org/10.1161/jaha.122.025551

Zhang, Y., Suo, Y., Yang, L., Zhang, X., Yu, Q., Zeng, M., Zhang, W., Jiang, X. and Wang, Y., 2022. Effect of PCSK9 inhibitor on blood lipid levels in patients with high and very‐high CVD risk: a systematic review and meta‐analysis. Cardiology Research and Practice, 2022(1), p.8729003.

https://doi.org/10.1155/2022/8729003

Deedwania, P., Murphy, S.A., Scheen, A., Badariene, J., Pineda, A.L., Honarpour, N., Keech, A.C., Sever, P.S., Pedersen, T.R., Sabatine, M.S. and Giugliano, R.P., 2021. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA cardiology, 6(2), pp.139-147.

https://doi.org/10.1001/jamacardio.2020.3151

Liu, D., Zhang, J., Zhang, X., Jiang, F., Wu, Y., Yang, B., Li, X., Fan, X., Li, H., Sun, Y. and Gou, R., 2024. The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis. Frontiers in Cardiovascular Medicine, 11, p.1454918. https://doi.org/10.3389/fcvm.2024.1454918

Rivera, F.B., Cha, S.W., Aparece, J.P., Rocimo, A., Ong, B.A., Golbin, J.M., Alfonso, P.G., Enkhmaa, B., Khan, S.U., Cainzos-Achirica, M. and Volgman, A.S., 2023. Sex differences in cardiovascular outcomes and cholesterol-lowering efficacy of PCSK9 inhibitors: systematic review and meta-analysis. JACC: Advances, 2(9), p.100669.

https://doi.org/10.1016/j.jacadv.2023.100669

Farhan, M., Hussein, G.A., Alom, T., Das, A., Durrani, T.A., Hayani, Z.M., Alkassar, A., Oweis, H.A., Nazir, M.H., Dhillon, D.K. and Servil, E., 2025. Evaluating the role of PCSK9 inhibitors in reducing cardiovascular events among statin-intolerant patients: a systematic review and meta-analysis. Annals of Medicine and Surgery, 87(2), pp.891-899.

https://doi.org/10.1097/ms9.0000000000002927

Wang, X., Wen, D., Chen, Y., Ma, L. and You, C., 2022. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovascular diabetology, 21(1), p.107.

https://doi.org/10.1186/s12933-022-01542-4

Hakim, D.I., Qhabibi, F.R., Yusuf, M., Amar, N., Prasetya, I. and Ambari, A.M., 2024. Safety and efficacy of PCSK9 inhibitors and effect on coronary plaque phenotype in statin-treated patients following acute coronary syndrome: a systematic review and meta-analysis. The Egyptian Heart Journal, 76(1), p.135.

https://doi.org/10.2139/ssrn.4704885